Fan Site: Inspired, Not Endorsed, By Rakesh Jhunjhunwala

Posts tagged Anand Narayan

Brahmal Vasudevan’s Idria Loses Fortune In ‘Pump N Dump’ Stock While Fears Plague Kenneth Andrade’s Fav Stock



PC-Jeweller

A stock in which Brahmal Vasudevan and other eminent experts reposed trust is suspected to be a bogus ‘pump and dump’ stock. We have to maintain red alert and monitor the situation minutely because the contagion may spread to Kenneth Andrade’s fav stock as well

Fav 5-Bagger Small-Cap Stock Of Brahmal Vasudevan’s Creador/ Latinia Has “Multiple Triggers” For Hefty Gains: Motilal Oswal



Brahmal Vasudevan’s Latinia has pocketed a mind-boggling gain of 400% from a small-cap stock in just 30 months. However, the stock deserves to bought even now because it has a lot more gains packed into it claims Motilal Oswal

Brahmal Vasudevan’s Creador Capital Scoops Up Mid-Cap Bank With Potential For Bumper Gains



Brahmal Vasudevan’s Creador Capital pocketed 450% gains from their last stock pick, Chola Finance. Their latest stock pick is of the same top-quality and pedigree and has the potential to give mega gains say eminent experts

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 493 other subscribers

RSS Stocks Talk Forum

  • Shalby is a multi-specialty hospital chain with expertise in joint replacement
    Shalby is a multi-specialty hospital chain with expertise in joint replacement. It is making right strides with calibrated growth based on big ticket expansion in metros & tier I cities & asset-light franchisee expansion in tier II-VI towns. TP ₹310 (35%) Download... Shalby is a multi-specialty hospital chain with expertise in joint replacement
  • DLF has strong growth prospects. Buy for target price of ₹1081 (30% upside)
    DLF has strong growth prospects due to strong sectoral tailwinds, record low inventory, greater preference for branded luxury, extensive launch pipeline & expansion in its annuity portfolio. Strong Balance Sheet with consistent cash flow. TP ₹1081 (+30%) Research Report... DLF has strong growth prospects. Buy for target price of ₹1081 (30% upside)
  • Aditya Birla Capital has demonstrated solid performance. Buy for target price of ₹280 (37% upside)
    Aditya Birla Capital has demonstrated solid performance, achieving strong growth in the loan book while maintaining asset quality. Management has reiterated guidance on both growth & credit cost fronts. Lending business expected to grow at 30%. TP (+37%)... Aditya Birla Capital has demonstrated solid performance. Buy for target price of ₹280 (37% upside)
Disclaimer: This is a Fan Site in Rakesh Jhunjhunwala's name. Rakesh Jhunjhunwala is not associated with us and is in no way aware, accountable or responsible for what is stated here. Further, nothing here constiutes investment advice for you to act on. Also, we have a vested interest, and are extremely biased, in everything that we say. So Mind It!